Stephens & Co. Initiates Coverage On Elevation Oncology with Overweight Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Sudan Loganathan initiates coverage on Elevation Oncology (NASDAQ:ELEV) with an Overweight rating and a price target of $8.
May 14, 2024 | 10:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elevation Oncology receives an Overweight rating from Stephens & Co. with a price target of $8, indicating a positive outlook from the analyst.
The initiation of coverage by Stephens & Co. with an Overweight rating and a specific price target suggests a strong positive sentiment towards Elevation Oncology's stock. This could lead to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100